Last reviewed · How we verify
Contrast enhanced Ultrasound
At a glance
| Generic name | Contrast enhanced Ultrasound |
|---|---|
| Also known as | CEUS, Optison |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder (NA)
- Artificial Intelligence-assisted Contrast-enhanced Ultrasound Diagnosis of Thyroid Nodules (NA)
- CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma
- Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy (EARLY_PHASE1)
- Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania (NA)
- Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging (PHASE4)
- Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NA)
- Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: